NCT02670720View on ClinicalTrials.gov

Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema

PHASE3TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Hereditary AngioedemaHAE
Interventions
DRUG

avoralstat

Trial Locations (3)

Unknown

Leuven

Grenoble

Lille

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY

NCT02670720 - Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema | Biotech Hunter | Biotech Hunter